Bristol Myers cuts PhIII PD-1/LAG-3 trial in colorectal cancer short after drug combo fails analysis

Bris­tol My­ers Squibb is ax­ing a Phase III tri­al in­ves­ti­gat­ing its com­bi­na­tion of nivolum­ab (Op­di­vo) and re­latlimab in col­orec­tal can­cer af­ter a da­ta mon­i­tor­ing com­mit­tee said it was “un­like­ly” to meet the pri­ma­ry end­points, the com­pa­ny said Fri­day.

In the Phase III REL­A­TIV­I­TY-123 study, BMS was in­ves­ti­gat­ing nivolum­ab plus re­latlimab in pa­tients with mi­crosatel­lite sta­ble metasta­t­ic col­orec­tal can­cer (mCRC) whose dis­ease has pro­gressed fol­low­ing at least one, though no more than four, pri­or lines of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.